MedPath

Immunohistochemical examination of the tolerance -inducing enzyme indoleamine 2,3 -dioxygenase ( IDO ) in melanoma as a prognostic marker for progression-free- and overall survival

Conditions
C43
Malignant melanoma of skin
Registration Number
DRKS00010682
Lead Sponsor
niversitätsklinik FreiburgDermatologie und Venerologie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
120
Inclusion Criteria

available paraffin sections from patients with melanoma +/- sentinel lymph node with tumor thicknesses of less than 1 mm , greater than or equal 4mm and metastasis of melanoma of unknown primary

Exclusion Criteria

none

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint is the correlation of the expression of the parameters with the progression-free and overall survival
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath